Release of calreticulin from neutrophils may alter C1q-mediated immune functions. 1997

U Kishore, and R D Sontheimer, and K N Sastry, and K S Zaner, and E G Zappi, and G R Hughes, and M A Khamashta, and P Strong, and K B Reid, and P Eggleton
Department of Biochemistry, University of Oxford, U.K.

Calreticulin is an abundant intracellular protein which is involved in a number of cellular functions. During cytomegalovirus infection, as well as inflammatory episodes in autoimmune disease, calreticulin can be released from cells and detected in the circulation, where it may act as an immunodominant autoantigen in diseases such as systemic lupus erythematosus. Calreticulin is known to bind to the molecules of innate immunity, such as C1q, the first subcomponent of complement. However, the functional implications of C1q-calreticulin interactions are unknown. In the present study we sought to investigate, in greater detail, the interaction between these two proteins following the release of calreticulin from neutrophils upon stimulation. In order to pinpoint the regions of interaction, recombinant calreticulin and its discrete domains (N-, P- and C-domains) were produced in Escherichia coli. Both the N- and P-domains of calreticulin were shown to bind to the globular head regions of C1q. Calreticulin also appeared to alter C1q-mediated immune functions. Binding of calreticulin to C1q inhibited haemolysis of IgM-sensitized erythrocytes. Both the N- and P-domains of calreticulin were found to contain sites involved in the inhibition of C1q-induced haemolysis. Full-length calreticulin, and its N- and P-domains, were also able to reduce the C1q-dependent binding of immune complexes to neutrophils. We conclude that calreticulin, once released from neutrophils during inflammation, may not only induce an antigenic reaction, but, under defined conditions, may also interfere with C1q-mediated inflammatory processes.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002135 Calcium-Binding Proteins Proteins to which calcium ions are bound. They can act as transport proteins, regulator proteins, or activator proteins. They typically contain EF HAND MOTIFS. Calcium Binding Protein,Calcium-Binding Protein,Calcium Binding Proteins,Binding Protein, Calcium,Binding Proteins, Calcium,Protein, Calcium Binding,Protein, Calcium-Binding
D003171 Complement Pathway, Classical Complement activation initiated by the binding of COMPLEMENT C1 to ANTIGEN-ANTIBODY COMPLEXES at the COMPLEMENT C1Q subunit. This leads to the sequential activation of COMPLEMENT C1R and COMPLEMENT C1S subunits. Activated C1s cleaves COMPLEMENT C4 and COMPLEMENT C2 forming the membrane-bound classical C3 CONVERTASE (C4B2A) and the subsequent C5 CONVERTASE (C4B2A3B) leading to cleavage of COMPLEMENT C5 and the assembly of COMPLEMENT MEMBRANE ATTACK COMPLEX. Classical Complement Pathway,Classical Complement Activation Pathway,Complement Activation Pathway, Classical
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D006461 Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity. Haemolysis,Extravascular Hemolysis,Intravascular Hemolysis,Extravascular Hemolyses,Haemolyses,Hemolyses, Extravascular,Hemolyses, Intravascular,Hemolysis, Extravascular,Hemolysis, Intravascular,Intravascular Hemolyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001324 Autoantigens Endogenous tissue constituents with the ability to interact with AUTOANTIBODIES and cause an immune response. Autoantigen,Autologous Antigen,Autologous Antigens,Self-Antigen,Self-Antigens,Antigen, Autologous,Antigens, Autologous,Self Antigen,Self Antigens

Related Publications

U Kishore, and R D Sontheimer, and K N Sastry, and K S Zaner, and E G Zappi, and G R Hughes, and M A Khamashta, and P Strong, and K B Reid, and P Eggleton
January 2020, Frontiers in immunology,
U Kishore, and R D Sontheimer, and K N Sastry, and K S Zaner, and E G Zappi, and G R Hughes, and M A Khamashta, and P Strong, and K B Reid, and P Eggleton
September 1994, Clinical immunology and immunopathology,
U Kishore, and R D Sontheimer, and K N Sastry, and K S Zaner, and E G Zappi, and G R Hughes, and M A Khamashta, and P Strong, and K B Reid, and P Eggleton
January 2023, Tropical medicine and infectious disease,
U Kishore, and R D Sontheimer, and K N Sastry, and K S Zaner, and E G Zappi, and G R Hughes, and M A Khamashta, and P Strong, and K B Reid, and P Eggleton
November 1996, FEBS letters,
U Kishore, and R D Sontheimer, and K N Sastry, and K S Zaner, and E G Zappi, and G R Hughes, and M A Khamashta, and P Strong, and K B Reid, and P Eggleton
January 2017, Frontiers in immunology,
U Kishore, and R D Sontheimer, and K N Sastry, and K S Zaner, and E G Zappi, and G R Hughes, and M A Khamashta, and P Strong, and K B Reid, and P Eggleton
May 2006, Arthritis and rheumatism,
U Kishore, and R D Sontheimer, and K N Sastry, and K S Zaner, and E G Zappi, and G R Hughes, and M A Khamashta, and P Strong, and K B Reid, and P Eggleton
January 1999, Lupus,
U Kishore, and R D Sontheimer, and K N Sastry, and K S Zaner, and E G Zappi, and G R Hughes, and M A Khamashta, and P Strong, and K B Reid, and P Eggleton
February 2020, Journal of immunology (Baltimore, Md. : 1950),
U Kishore, and R D Sontheimer, and K N Sastry, and K S Zaner, and E G Zappi, and G R Hughes, and M A Khamashta, and P Strong, and K B Reid, and P Eggleton
June 2012, Infection and immunity,
U Kishore, and R D Sontheimer, and K N Sastry, and K S Zaner, and E G Zappi, and G R Hughes, and M A Khamashta, and P Strong, and K B Reid, and P Eggleton
December 1997, Immunopharmacology,
Copied contents to your clipboard!